These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23824362)

  • 1. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
    Kadouri L; Sagi M; Goldberg Y; Lerer I; Hamburger T; Peretz T
    Breast Cancer Res Treat; 2013 Jul; 140(1):207-11. PubMed ID: 23824362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    Huszno J; Budryk M; Kołosza Z; Nowara E
    Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
    Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
    Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
    Cibula D; Zikan M; Dusek L; Majek O
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
    Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
    Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.